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Hydrophilic polyphosphoester-conjugated
fluorinated chlorin as an entirely biodegradable
nano-photosensitizer for reliable and eﬃcient
photodynamic therapy†
Zhiyong Liu,a Mengsi Wu,a Yudong Xue,a Chao Chen, b Frederik R. Wurm, *c
Minbo Lan a and Weian Zhang *a
An entirely biodegradable nano-photosensitizer platform (PPE-FP2) was
fabricated by conjugating the photosensitizer TFPC to hydrophilic
polyphosphoesters (PPEs) for eﬃciently liberating photosensitizers
at the tumor site. The complete biodegradability of PPE-FP2 avoided
residual nanoparticles in vivo after therapy, realizing reliable and
eﬀective photodynamic therapy.
Nanocarriers such as liposomes,1,2 polymer micelles,3,4 MOFs5–7
and inorganic nanoparticles8,9 have been fabricated to deliver
drugs to tumor cells via the enhanced permeability and retention
(EPR) effect.10,11 In particular, pegylated nanoparticles have
received massive attention. However, PEG cannot be biodegraded
in vivo. Several concerns associated with the non-biodegradability
of PEG have been raised, especially for long-term administration.12
The accumulation of PEG in vivo has been reported to result in
intracellular vacuolation of organs such as the renal tubules,
due to the stability of PEG.13 Furthermore, the formation of PEG
antibodies has been observed, which can induce immune
responses and accelerate the clearance of nanoparticles modi-
fied by PEG.14 To address the defects of non-biodegradable PEG,
novel stealth polymers such as polyphosphoesters (PPEs),15
and also zwitterionic polymers,16–18 hydroxyethyl starch19,20 or
dextrin21 have been proposed.
PPEs present great potential as a stealth material due to
their biocompatibility and biodegradability.22 The backbone of
PPEs is similar to biomacromolecules, such as DNA, RNA and
teichoic acids and phosphorus is a fundamental element of
bone making up 1% of the total human body mass.23,24 Therefore,
the final degradation products of PPEs, phosphate or phosphonate,
exist in or are well tolerated by the human body. Moreover, the
backbone of PPEs can be cleaved under physiological conditions
or recognized by enzymes, such as alkaline phosphatase, which
is increased in tumor cells and can accelerate the hydrolysis of
PPEs.25,26 Furthermore, the hydrolysis rate and functionality of
PPEs can be controlled by side chain attachment resulting from
reactive pendant groups of pentavalent phosphorus.27 Based on
PPEs, Wooley et al. have designed several types of micelles used
for drug delivery and gene therapy.28,29 In addition, Wang et al.
also reported PPE-based nanoparticles for improving the anti-
tumor eﬀect of drugs.30,31 Importantly, as a stealth biomaterial,
hydrophilic PPE has been verified to reduce protein adsorption
and prevent nonspecific cellular uptake as well as PEG.32
Consequently, an eﬀective and secure therapy could be achieved
by a direct conjugation of PPE with hydrophobic agents.
Herein, we developed a fully biodegradable polymer photo-
sensitizer by conjugating 7,8-dihydro-5,10,15,20-tetrakis(penta-
fluorophenyl)-21H,23H-porphine (TFPC) to the hydroxyl end
groups of a telechelic poly(methyl ethylene phosphate) (PPE)
as shown in Scheme 1. PPE is a hydrophilic polymer and after
conjugation will self-assemble into larger aggregates with a PPE
shell that should reduce protein adsorption. TFPC as a hydro-
phobic macrocyclic aromatic compound is easy to aggregate
through p–p stacking and hydrophobic interaction; therefore,
the polymer-photosensitizer conjugate can assemble into nano-
particles and accumulate in tumor sites by the EPR effect.
Moreover, PPEs can be degraded in a physiological environment
or by phosphatase, thus TFPC could be released from the nano-
particles for enhancing the sensitivity of photosensitizers to
oxygen. Furthermore, the degradation of the nanoparticles can
avoid their in vivo accumulation after therapy, reducing the side
effects.
Meso-tetrakis(pentafluorophenyl)porphyrin (TFPP) was synthe-
sized and then reduced by p-toluenesulfonylhydrazide to obtain
the red-light-absorbing photosensitizer TFPC as shown in
Scheme S1 (ESI†). Di-hydroxyl functionalized PPE with a molar
mass of 4000 g mol1 was synthesized by anionic ring-opening
polymerization by an adapted literature protocol as the stealth
material.33 PPE-FP2 was prepared by conjugation of TFPC to
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PPE via esterification as shown in Scheme S1 (ESI†) and further
assembled into spherical nanoparticles. Additionally, the
PEG-analog, PEG-FP2 (Scheme S2, ESI†) was also prepared via
a similar approach as a non-degradable control (detailed charac-
terization is given in Fig. S1–S11, ESI†). Both polymer conjugates,
PPE-FP2 and PEG-FP2 could be dispersed well in water and by the
naked eye generated a stable dispersion with the typical yellowish
color of the chlorin. In contrast, hydrophobic TFPC remained
insoluble and sedimented. For both PPE-FP2 and PEG-FP2, sphe-
rical nanoparticles could be observed after the self-assembly by
transmission electron microscopy (TEM) images (Fig. 1b and c).
The size of the nanoparticles was relatively uniform for both
PPE-FP2 and PEG-FP2 with average diameters of ca. 100 nm and
110 nm, respectively. Dynamic light scattering (DLS) further
confirmed the size of the nanoparticles and supported the
relatively narrow size distribution (Fig. 1d, an average hydro-
dynamic size of 160 nm, which is slightly larger than that
determined by TEM, probably due to hydration). Subsequently,
the potentials for photodynamic therapy and fluorescence
imaging of PPE-FP2 were evaluated by UV absorbance spectrum
in Fig. 1e and fluorescence emission spectroscopy in Fig. 1f,
which show that PPE-FP2 nanoparticles have strong absorption
(655 nm, e(TFPC) = 1.62  104 L (mol1 cm1)) and emission
(600–750 nm) in the far-red light region; therefore, PPE-FP2
nanoparticles could be used as a potential agent for the
diagnosis of solid tumors.
The in vitro biodegradability of the PPE-FP2 conjugate was
separately assessed after direct dispersion in phosphate-buﬀered
saline at pH = 7.4 and after the addition of alkaline phosphatase
(ALP) while being shaken on a horizontal shaker at 37 1C. It is
known that the concentration of ALP is increased in tumor cells,
which should lead to an accelerated degradation of PPE.25 The
degradation of PPE-FP2 in PBS with or without ALP was proven
by UV absorbance and DLS measurements after certain time
intervals (Fig. 2a–e and Fig. S12 and S13, ESI†). Compared with
dispersion in PBS without ALP, the degradation rate of PPE-FP2
nanoparticles increased significantly in the presence of ALP,
resulting in greater absorption reduction during 24 h as shown
in Fig. 2b and c, which would promote photosensitizers to be
effectively released from the PPE-FP2 nanoparticles at tumor sites.
Degradation was followed by DLS (as shown in Fig. 2d and e and
Fig. S13, ESI†): the size distribution of PEG-FP2 nanoparticles
remained nearly unchanged, as they remained hydrolytically
stable under these conditions, while the colloidal stability of
the degradation products from PPE-FP2 decreased as the PPE
hydrolyzed, resulting in aggregation of the hydrophobic chlorin.
In the presence of ALP, PPE-FP2 nanoparticles were quickly
destabilized during the first day, which further proved the
biodegradation behavior of PPE accelerated by ALP. TEM
images shown in Fig. S14–S18 (ESI†) also demonstrated that
PPE-FP2 nanoparticles without the presence of ALP could
maintain their distribution during the first day and degrade
to irregular assembled aggregates after 3 days.
Reactive oxygen species (ROS) generation of the nano-
particles was confirmed by using 1,3-diphenylisobenzofuran
(DPBF) as an ROS indicator before investigating the in vitro and
in vivo PDT performance.34 ROS generated by nanoparticles
Scheme 1 Schematic illustration of the self-assembly and application in
photodynamic therapy of PPE-FP2.
Fig. 1 Characterization of PEG-FP2 and PPE-FP2 nanoparticles. (a) Photo-
graphs of TFPC, PEG-FP2 and PPE-FP2 in water. (b and c) TEM images of
PEG-FP2 and PPE-FP2 nanoparticles. (d) Dynamic light scattering data of
the nanoparticles. (e) UV spectra and (f) fluorescence spectra (ex: 425 nm)
in ultrapure water.
Fig. 2 Stability evaluation of PPE-FP2 under diﬀerent conditions. (a) Photos
taken from the dispersions over time. UV spectrum of PPE-FP2 dispersed in
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under 655 nm laser irradiation were recorded by a decrease of
characteristic absorption of DPBF at ca. 415 nm (Fig. S19, ESI†).
This result proved that both PPE-FP2 and PEG-FP2 nano-
particles could be used to as antitumor agents in PDT.
Confocal laser scanning microscopy (CLSM) was used to
determine the cellular uptake of the nanoparticles. As shown
in Fig. 3a, both PPE-FP2 and PEG-FP2 nanoparticles could be
taken up eﬀectively after incubating with 4T1 cells for 24 h.
Interestingly, the fluorescence intensity of the cells treated with
PPE-FP2 after 24 h was higher than that of the cells incubated
with PEG-FP2, which might be a result of the degradation of
PPE-FP2 after internalization into the tumor cells. Flow cyto-
metry was used to study the cellular uptake of the chlorin
conjugates (Fig. S20, ESI†). Gradually enhanced intracellular
fluorescence intensity was observed with prolonged incubation
times for both PPE-FP2 and PEG-FP2, indicating eﬃcient inter-
nalization of the nanoparticles. Specifically, we found that the
curves of fluorescence intensity of PPE-FP2 had two peaks at 4 h
while there was only one peak at 24 h, indicating that PPE could
be gradually degraded. Moreover, the higher fluorescence
intensity of TFPC was observed in tumor cells treated with
PPE-FP2 compared with cells incubated with PEG-FP2. These
results suggested that PPE-FP2 could be gradually degraded to
release TFPC in cells, thus reducing the aggregation induced
quenching eﬀect, which might enhance the PDT eﬀect.
To gain insight into the PDT ability of PPE-FP2, the intra-
cellular ROS generation of PPE-FP2 was evaluated by using
2,7-dichlorofluorescein diacetate (DCFH-DA) as an ROS probe.35
As shown in Fig. 3b, when combined with laser irradiation,
the green fluorescence intensity of PPE-FP2 was significantly
increased compared to that of the control, while PEG-FP2
exhibited a moderate enhancement of fluorescence. This result
indicated the mass production of intracellular ROS induced by
the nanoparticles under 655 nm laser irradiation, especially for
biodegradable PPE-FP2. Based on these results, the in vitro PDT
eﬀect against 4T1 cells was verified viaMTT assay. The cell viability
approved in Fig. 3c demonstrated that PPE-FP2 and PEG-FP2 both
have no significant cytotoxicity without laser irradiation on account
of their good biocompatibility. However, when the cells incubated
with nanoparticles were irradiated with a 655 nm laser, the cell
viability showed a prominent decrease with the increase of
the concentration of nanoparticles. Moreover, PPE-FP2 (IC50:
24 mg mL1, calculated for chlorin concentration) exhibited a
more eﬃcient therapeutic eﬀect than PEG-FP2 (IC50: 42 mg mL
1),
which may have resulted from the biodegradation of PPE-FP2
accompanied by the liberation of TFPC.
Near infrared fluorescence agent Cyanine 7 (Cy7), a fluores-
cence quenching agent of TFPC based on fluorescence reso-
nance energy transfer (FRET),36 was co-assembled with PPE-FP2
for in vivo fluorescence imaging as shown in Fig. 4a. The
successful encapsulation of Cy7 is determined by UV spectra
and DLS (Fig. S21 and S22, ESI†). The fluorescence imaging
monitored in real-time revealed that nanoparticles could gra-
dually accumulate into the tumor site with the extension of
time and show a strong fluorescence signal at the tumor site at
24 h post-injection (p.i.). This consequence demonstrated that
nanoparticles could eﬀectively deliver TFPC into the tumor site
through the EPR eﬀect.
Encouraged by the remarkable previous consequences,
4T1-tumor-bearing mice were used to investigate the in vivo
anti-tumor performance. The mice were randomly divided into
five groups: control, PEG-FP2, PPE-FP2, PEG-FP2 + L (655 nm
laser irradiation), and PPE-FP2 + L. Relative tumor volume was
recorded to study the suppressive eﬀect as shown in Fig. 4b.
The PEG-FP2 + L and PPE-FP2 + L groups showed a remarkable
delay in tumor growth or tumor regression as compared with
the control groups after 18 days. To further underline the
Fig. 3 Intracellular distribution and in vitro photodynamic therapy. CLSM
images of (a) endocytosis by 4T1 cells and (b) intracellular ROS detected by
DCFH-DA as a fluorescent probe. Cell viability against 4T1 cells (c) without
and (d) with 655 nm laser (100 mW cm2, 10 min) evaluated by MTT assay
after incubation with PEG-FP2 and PPE-FP2 for 24 h.
Fig. 4 In vivo fluorescence imaging and anti-tumor eﬃcacy against 4T1
tumors after intravenous injection of PBS (control), PEG-FP2 and PPE-FP2
nanoparticles at a TFPC-equivalent dose of 1 mg kg1. (a) Cy7 (ex: 700 nm,
em: 780 nm). (b) Relative tumor volumes. (c) Body weight and (d) tumor
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eﬃciency of phototherapy, the tumors were excised from the
mice and weighed to obtain the accurate tumor weight after the
mice were sacrificed on day 18. As shown in Fig. 4d and e,
tumors irradiated by a laser successfully reduced the size and
weight, indicating the eﬃcient photodynamic anti-tumor eﬀect
of PPE-FP2 and PEG-FP2. Besides, we found that there is a slow
growth trend for tumors in the PEG-FP2 + L group while no
obvious change in the PPE-FP2 + L group was observed, which
could be attributed to the biodegradation behavior of PPE-FP2
with the enhanced PDT eﬃcacy. Qualitative histological exami-
nations were also carried out by hematoxylin and eosin (H&E)
staining of tumor slices (Fig. S23, ESI†). Significant necrosis
was observed on groups irradiated with a laser, especially for
the PPE-FP2 + L group, proving the evident destruction of tumor
cells by phototherapy. Fig. 4c and Fig. S24 (ESI†) revealed the
minimal side eﬀects of PEG-FP2 and PPE-FP2 during treatment.
A major benefit of PPE is the hydrolytic lability; thus, we
increased the dose of the chlorin conjugates. The mice were
sacrificed after two months, and then the kidneys and spleens
were harvested and stained by H&E for toxicity analysis. Fig. S25
(ESI†) revealed that the kidneys, and spleens of mice adminis-
tered with PEG-FP2 were damaged distinctly. In contrast, those
treated with PPE-FP2 showed almost no damage. These results
could be attributed to the degradation of PPEs avoiding the
long-term accumulation of nanoparticles in the organs, indicating
that the biodegradability of PPE endowed PPE-FP2 with excellent
biological safety.
In summary, by conjugating TFPC to PPE, we developed a
biodegradable nano-photosensitizer (PPE-FP2) for safe and
eﬀective photodynamic therapy. PPE-FP2 can be assembled into
spherical nanoparticles and accumulate in tumor cells via the
EPR eﬀect. In addition, benefiting from the eﬀective far-red
absorption, PPE-FP2 could achieve deep tumor penetration.
Importantly, as PPE-FP2 could be degraded, TFPC can be released
from the assembly after cellular uptake, increasing the photo-
dynamic eﬃcacy of the PPE-conjugates, compared to the non-
degradable PEGylated analog. In addition, as PPE-FP2 can be
degraded and did not show any cytotoxicity in the absence of
light, long-term in vivo accumulation is prevented. We believe that
the nano-photosensitizers based on PPE are a new platform to
design safe and more eﬃcient photodynamic therapies. Together
with the potential chemical functionality of PPEs, further targeting
ligands or variation in their biodegradation profile can be
installed, which will be studied in future projects.
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